Biomoda Inc. Contracts with Leading Clinical Pathology Firm; Former Becton Dickinson Medical Director to Aid Company.ALBUQUERQUE, N.M. -- The name "Hofgartner" was inadvertently misspelled. The name should read: Hofgartner (sted Hoftgartner). The corrected release reads: BIOMODA INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . CONTRACTS WITH LEADING CLINICAL PATHOLOGY clinical pathology n. 1. The practice of pathology as it pertains to the care of patients. 2. The subspecialty in pathology concerned with the theoretical and technical aspects of laboratory technology that pertain to the FIRM; FORMER BECTON DICKINSON BD (NYSE: BDX), is a medical technology company that manufactures and sells medical devices, instrument systems and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs 27,000 people in nearly 50 countries. MEDICAL DIRECTOR TO AID COMPANY Biomoda Inc. has announced the addition of a leading clinical pathology consulting firm, Esocor LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , www.esocor.com, White Plains, N.Y., to the group of world-class professionals who have contracted with Biomoda to assist and assure that Biomoda's patented and critically needed products, primarily involved with early detection and targeted treatment of specific cancers, are brought to market in an orderly and expedited manner. Esocor's Managing Director Dr. Wolfgang Hofgartner, a world-recognized board-certified clinical pathologist, will support Biomoda's product entry to offer the company's patented systems and treatments. Hofgartner, a medical doctor and doctor of sciences, has built and cultivated a multinational network of academic opinion leaders in clinical pathology. Hofgartner has conducted clinical research in conjunction with world-class institutions including Sloan Kettering Cancer Center and Baylor College of Medicine Baylor College of Medicine is a private medical school located in Houston, Texas, USA on the grounds of the Texas Medical Center. It has been consistently rated the top medical school in Texas and among the best in the United States. , and served as European medical director for Becton Dickinson (Fortune 500 healthcare). Hofgartner will be part of Biomoda's carefully assembled team of leading outside medical professionals. Biomoda looks to his significant European experience to provide a head start for the company's global marketing. Biomoda Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The company, exclusive worldwide licensee from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). of several patents developed for noninvasive early detection and treatment of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , is in the process of registering additional patents in this area. The company's proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products. Operating from its laboratory situated at Kirtland Air Force Base Kirtland Air Force Base is located in the southeast quadrant of Albuquerque, New Mexico, adjacent to the Albuquerque International Sunport. The base is the third largest installation in Air Force Materiel Command, covering 51,558 acres (209 km²) and employing over 23,000 people, (Albuquerque, N.M.), the company is in the process of expanding and expediting its product development and commercialization with a number of strategic alliances that will be announced over the next 60 days. This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates" and words of similar import. The company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. . For additional information, visit the Biomoda Web site at www.biomoda.com or call us at 505-821-0875. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion